School Health ServicesPEERNCT07412743
Multilevel Peer-to-Peer HPV Vaccination and Wellness Educational Program in School Based Health Centers
A study testing Mailers, Provider Materials and Peer-to-Peer Educational Sessions in people with School Health Services, run by Kaiser Permanente at 1 site in United States.
Trial summary
School-based health centers (SBHCs) are an important setting to improve health through detecting, managing and preventing chronic illness. Too few people are educated about the human papillomavirus (HPV), which can prevent tens of thousands of deaths from cancer each year. Read more about this study
- Who is it for?
- Ages 9 to 18 years
- Conditions the study is for
- School Health Services
- What is being tested?
- Mailers, Provider Materials and Peer-to-Peer Educational Sessions
- Type of treatment
- Vaccines, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 4,000 participants
- Where
- 1 siteUnited States
- Study dates
- 12 Jan 2026to Jun 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 9 to 18 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- Aged 9-18
- New or established patients
- Flagged if due for an HPV vaccine
Who cannot join
- None
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
Kaiser Permanente Center for Health Research
Portland, Oregon, 97227
About this study
School-based health centers (SBHCs) are an important setting to improve health through detecting, managing and preventing chronic illness. Too few people are educated about the human papillomavirus (HPV), which can prevent tens of thousands of deaths from cancer each year. PEER will evaluate a program to increase health and wellness and the use of SBHCs for primary and preventive care. If successful, PEER could significantly increase the use of SBHCs, and decrease HPV-associated cancers and, thus, reduce the burden of cancer in the United States.
- Conditions
- School Health Services
- Being tested
- Mailers, Provider Materials, Peer-to-Peer Educational Sessions
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MailersBehavioural
Letter and fact sheet (infographic) mailed to caregivers of 9-14 year-olds and to teens 15-18, with optional phone call for "confidential patients" aged 15-18.
Provider MaterialsBehavioural
Clinic team/staff training based on qualitative interviews, recommended strategies and evidence-based interventions. Training materials include FAQs and Smart phrases. FAQs and informational sheets containing the same content as the mailers distributed in clinic to teen SBHC patients and their caregivers.
Peer-to-Peer Educational SessionsBehavioural
Educational sessions delivered in schools by OSBHA interns. Session content includes SBHC information and HPV awareness.
| Study group | Role | What they receive |
|---|---|---|
| Control time (pre-implementation) | No intervention | All participating SBHCs offer routine HPV vaccination recommendations as part of clinical care and SBHC staff will continue to follow standard procedures to deliver these services. Further, all SBHCs have existing relationships with the affiliated schools, so the delivery of these healthcare services in the context of schools will not deviate from usual care. |
| Intervention (post-implementation) | Experimental | Intervention components (mailers, provider materials, and peer-to-peer educational sessions) will be administered during the intervention portion of each cluster. Receives: Behavioral: Mailers; Behavioral: Provider Materials; Behavioral: Peer-to-Peer Educational Sessions |
What is being measured
The primary outcome is the main question the study is designed to answer.
Rate of Vaccination for HPV (n of patients with HPV vaccination/n of patients eligible for vaccination)
Vaccination among eligible clinic patients, and time to vaccination
Measured: 6 and 12 months
Secondary outcomes (3)
Rates of new patients to the clinic (n of new patients/n of established patients)
New patients seen (vs. prior seen pts.) - New patient characteristics (age, rural)
Measured: 6 and 12 months
Rate of use of other SBHC services (primary care visits, wellness assessments) (n of patients with primary care visits/n of new and established patients)
Use of other SBHC services and visits among eligible clinic patients
Measured: 6 and 12 months
Rate of vaccination for other adolescent vaccinations (COVID-19, flu, Meningitis, or uptick of other vax's (TDAP, MMR, etc.)) (n of patients with additional vaccination among new and eligible clinic patients)
Vaccination among eligible clinic patients, and time to vaccination
Measured: 6 and 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Feb 2026
- Study start12 Jan 2026
- Primary completionAug 2028 (estimated)
- Study completionJun 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for School Health ServicesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- The PEER study is a concurrent stepped wedge and patient randomized trial that will take place in 9 School Based Health Centers (SBHCs) in Oregon serviced by Multnomah County Health Department (MC) clinics. All clusters start in control and cross over in a randomized, staggered fashion, with all eventually receiving the intervention.
- Masking
- None (open label)
- Enrolment
- 4,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Kaiser Permanente
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute on Minority Health and Health Disparities (NIMHD)
- Responsible party
- Sponsor
- Investigators
- Amanda Petrik, PhD, Principal investigator, Kaiser Permanente
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07412743
- Sponsor's protocol ID
- R01MD019038-01A1
- Other IDs
- R01MD019038
- Acronym
- PEER
- Status last verified
- Apr 2026
- First submitted
- 6 Feb 2026
- Last updated
- 1 May 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Deidentified data and accompanying data dictionaries will be stored for future sharing as anonymized data sets in a data repository per NIH data sharing requirements.
Study at a glance
From the registry record, last updated by the sponsor on 1 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Multilevel Peer-to-Peer HPV Vaccination and Wellness Educational Program in School Based Health Centers
- ClinicalTrials.gov ID
- NCT07412743
- Acronym / sponsor ID
- PEER / R01MD019038-01A1
- Conditions
- School Health Services
- Study type
- Interventional
- Recruitment status
- Enrolling by invitation
- Enrolment
- 4,000 participants (estimated)
- Lead sponsor
- Kaiser PermanenteUniversity, hospital or other
- Collaborators
- National Institute on Minority Health and Health Disparities (NIMHD)
- Study start
- 12 Jan 2026 (actual)
- Primary completion
- Aug 2028 (estimated)
- Study completion
- Jun 2029 (estimated)
- First posted
- 17 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
School-based health centers (SBHCs) are an important setting to improve health through detecting, managing and preventing chronic illness. Too few people are educated about the human papillomavirus (HPV), which can prevent tens of thousands of deaths from cancer each year. PEER will evaluate a program to increase health and wellness and the use of SBHCs for primary and preventive care. If successful, PEER could significantly increase the use of SBHCs, and decrease HPV-associated cancers and, thus, reduce the burden of cancer in the United States.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- The PEER study is a concurrent stepped wedge and patient randomized trial that will take place in 9 School Based Health Centers (SBHCs) in Oregon serviced by Multnomah County Health Department (MC) clinics. All clusters start in control and cross over in a randomized, staggered fashion, with all eventually receiving the intervention.
| Arm | Type | Receives |
|---|---|---|
| Control time (pre-implementation) | No intervention | –All participating SBHCs offer routine HPV vaccination recommendations as part of clinical care and SBHC staff will continue to follow standard procedures to deliver these services. Further, all SBHCs have existing relationships with the affiliated schools, so the delivery of these healthcare services in the context of schools will not deviate from usual care. |
| Intervention (post-implementation) | Experimental | Behavioral: Mailers, Behavioral: Provider Materials, Behavioral: Peer-to-Peer Educational SessionsIntervention components (mailers, provider materials, and peer-to-peer educational sessions) will be administered during the intervention portion of each cluster. |
Who may qualify
- Ages
- 9 to 18 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (3 listed)
- Aged 9-18
- New or established patients
- Flagged if due for an HPV vaccine
Key exclusion criteria (1 listed)
- None
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MailersLetter and fact sheet (infographic) mailed to caregivers of 9-14 year-olds and to teens 15-18, with optional phone call for "confidential patients" aged 15-18. | Behavioural | Intervention (post-implementation) |
| Provider MaterialsClinic team/staff training based on qualitative interviews, recommended strategies and evidence-based interventions. Training materials include FAQs and Smart phrases. FAQs and informational sheets containing the same content as the mailers distributed in clinic to teen SBHC patients and their caregivers. | Behavioural | Intervention (post-implementation) |
| Peer-to-Peer Educational SessionsEducational sessions delivered in schools by OSBHA interns. Session content includes SBHC information and HPV awareness. | Behavioural | Intervention (post-implementation) |
Primary outcome
Rate of Vaccination for HPV (n of patients with HPV vaccination/n of patients eligible for vaccination)
Time frame: 6 and 12 months
Vaccination among eligible clinic patients, and time to vaccination
3 secondary outcomes
Rates of new patients to the clinic (n of new patients/n of established patients)
Time frame: 6 and 12 months
Rate of use of other SBHC services (primary care visits, wellness assessments) (n of patients with primary care visits/n of new and established patients)
Time frame: 6 and 12 months
Rate of vaccination for other adolescent vaccinations (COVID-19, flu, Meningitis, or uptick of other vax's (TDAP, MMR, etc.)) (n of patients with additional vaccination among new and eligible clinic patients)
Time frame: 6 and 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 May 2026.
- Individual participant dataSharing planned: No. Deidentified data and accompanying data dictionaries will be stored for future sharing as anonymized data sets in a data repository per NIH data sharing requirements.
Related trials for School Health Services
Not yet recruiting
Estimating the Impact of Sexuality Education and Mobile Health Services on Reproductive Health and Empowerment Among Adolescents in Sierra Leone for the Family Planning Impact Lab
Reproductive Health, Sexual Health
Recruiting
Resources and Education for Addressing Chronic Health (REACH)
Asthma (Diagnosis)
Recruiting
Impact Evaluation of Accelerating Climate-Resilient Water, Sanitation and Hygiene Services for Schools and Healthcare Facilities in Karamoja
Diarrhea, Respiratory Tract Infections (RTI)
RecruitingPhase 4
Latent Infection Freshmen Tracking for Tuberculosis
Latent Tuberculosis Infection (LTBI), Tuberculosis (TB)
Not yet recruiting
Recovery Opportunities Through Ongoing Treatment Sustainment
Substance Use Disorders (SUDs)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Amanda Petrik, PhD principal investigator
Kaiser Permanente
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Mailers, Provider Materials and Peer-to-Peer Educational Sessions in people with School Health Services, run by Kaiser Permanente at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 1 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Rate of Vaccination for HPV (n of patients with HPV vaccination/n of patients eligible for vaccination) (time frame: 6 and 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 May 2026.